Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin

Aaron M. LeBeau,1 W. Nathaniel Brennen,1 Saurabh Aggarwal,2 and Samuel R. Denmeade1,2,3

Departments of 1Pharmacology and Molecular Sciences and 2Chemical and Biomolecular Engineering, and 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Johns Hopkins University, Baltimore Maryland

Abstract
Fibroblast-Activation Protein-α (FAP) is a membrane-bound serine protease that is expressed on the surface of reactive stromal fibroblasts present within the majority of human epithelial tumors but is not expressed by normal tissues. FAP is a postprolyl peptidase that differs from other dipeptidyl prolyl peptidases such as diprolylpeptidase 4 in that it also has gelatinase and collagenase endopeptidase activity. Therefore, FAP represents a potential pan-tumor target whose enzymatic activity can be exploited for the intratumoral activation of prodrugs and protoxins. To evaluate FAP as a tumor-specific target, putative FAP-selective peptide protoxins were constructed through modification of the prodomain of melittin, a 26 amino acid amphipathic cytolytic peptide that is the main toxic component in the venom of the common European honeybee Apis mellifera. Melittin is synthesized as promelittin, containing a 22 amino acid NH2-terminal prodomain rich in the amino acids proline and alanine. In this study, peptides containing truncated melittin prodomain sequences were tested on erythrocytes to determine the optimal prodomain length for inhibiting cytolytic activity. Once optimized, modified promelittin peptides were generated in which previously identified FAP substrate sequences were introduced into the prodomain. Peptide protoxins were identified that were efficiently activated by FAP and selectively toxic to FAP-expressing cell lines with an IC50 value in the low micromolar range that is similar to melittin. Intratumoral injection of an FAP-activated protoxin produced significant lysis and growth inhibition of human breast and prostate cancer xenografts with minimal toxicity to the host animal. [Mol Cancer Ther 2009;8(5):1378–86]

Introduction
The growth of an epithelial neoplasm requires the formation of a supporting tumor stroma to supply nutrients and growth factors for tumor cell survival and continued growth. This invasive growth is associated with characteristic changes in the supporting stroma that include the induction of tumor blood vessel formation; the recruitment of reactive stromal fibroblasts, lymphocytes, and macrophages; the release of peptide-signaling molecules and proteases; and the production of an altered extracellular matrix (1–5). The tumor stroma compartment represents a major component of the mass of most carcinomas, with 20% to 50% commonly seen in breast, lung, and colorectal cancers and reaching >90% in carcinomas that have desmoplastic reactions (5, 6).

Reactive tumor stromal fibroblasts differ from fibroblasts of normal adult tissues with regard to morphology, gene expression profiles, and production of important biological mediators such as growth factors and proteases (1, 7, 8). A highly consistent trait of tumor stromal fibroblasts is the induction of the membrane-bound serine protease fibroblast-activation protein-α (FAP). FAP was originally identified as an inducible antigen expressed on reactive stroma and given the name Fibroblast Activation Protein. FAP was independently identified by a second group as a gelatinase expressed by aggressive melanoma cell lines and was given the name “seprase” for surface expressed protease (9). Subsequent cloning of FAP and seprase revealed that they are the same cell-surface serine protease (10).

FAP was originally reported to be a cell-surface antigen recognized by the F19 monoclonal antibody on human astrocytes and sarcoma cell lines in vitro (11). In one series using human tissues, FAP was detected in the stroma of over 90% of malignant breast, colorectal, skin, and pancreatic tumors (7, 11). In a small study, FAP was detected in the stroma of 7 of 7 prostate cancers (12). FAP is also expressed by a subset of soft tissue and bone sarcomas (7). FAP-positive fibroblasts also accompany newly formed tumor blood vessels (10). In nonmalignant tissue, FAP is expressed by reactive fibroblasts in wound healing, rheumatoid arthritis, liver cirrhosis, and in some fetal menenchymal tissues (7). Cheng et al. (13) also showed that, such as human FAP, mouse FAP is expressed by reactive fibroblasts within human cancer xenografts. In contrast, most normal adult tissues show no detectable FAP protein expression (7). In a recent study, Chiardi et al. (14) used real-time PCR to quantify gene expression from laser
capture disected tumor endothelium and found a significant increase in FAP expression compared with normal endothelium. This suggests that FAP expression may also be induced in both reactive tumor stroma and endothelium.

FAP is a member of the enzyme class known as postprolyl peptidases that are uniquely capable of cleaving the Pro-Xxx amino acid bond (15). This group of proteases includes the well-characterized dipeptidyl peptidase 4 (DPP4) as well as DPP2, DPP6, DPP7, DPP8, DPP9, prolyl carboxypeptidase, and prolyl endopeptidase. The substrate preferences for many of these prolyl peptidases are not entirely known but, such as DPP4, they all have dipeptidase activity. Like DPP4, FAP is a type II integral membrane protein able to cleave peptides containing proline as the penultimate amino acid. FAP differs from DPP4 in that it also has gelatinase and collagenase activity (16). This additional gelatinase/collagenase activity may be unique to FAP among the family of prolyl proteases.

The selective tumor expression and unique enzymatic activity of FAP make it a potentially attractive therapeutic target. Recently, our laboratory mapped all of the FAP cleavage sites in recombinant human gelatin and identified a series of peptide substrates that are efficiently cleaved by FAP (17). These peptide substrates can be coupled to cytotoxic small molecules to make FAP-activated prodrugs. Alternatively, the peptides could be incorporated into the activation domain of cytolytic proteins and peptides to produce FAP-activated protoxins. In this regard, we have generated an FAP-activated peptide toxin by incorporating an FAP-selective peptide sequence into the promdomain of the cytolytic peptide melittin.

Melittin, a 26 amino acid amphipathic peptide, is the main toxic component in the venom of the common European honeybee Apis melifera (18). The ability of melittin to induce the lysis of prokaryotic and eukaryotic cells has been well-documented (19–21). The exact mechanism by which melittin disrupts both natural and synthetic phospholipid bilayers is still largely unknown. In an aqueous milieu, melittin has a net +6 charge and exists as a random coiled monomer. It has been suggested that melittin can produce its toxic effects either by forming a transmembrane pore structure made up of melittin aggregates or by binding to the membrane surface and acting in a detergent-like manner leading to an increase in membrane permeability (18, 21).

In the honeybee, melittin is secreted into the venom glands as promelittin possessing an NH2-terminal prodomain made up of 22 amino acids. The promdomain is highly negatively charged containing nine acidic amino acid residues (22). The presence of the promdomain confers an overall negative charge to the molecule and decreases the ability of melittin to interact with the surface of the cell membrane. In the promdomain amino acid sequence, every second amino acid is either proline or alanine. Promelittin activation in vivo is the result of the stepwise cleavage of the promdomain into 11 dipeptide fragments by a DPP4-like protease present in honeybee venom gland extracts (22). By acetylation of the promelittin peptide or adding an extra amino acid residue at the NH2 terminus, the stepwise activation of promelittin by DPP4 dipeptidase activity is prevented. This observation suggested that the promelittin promdomain could be readily reengineered to produce a promdomain that can be removed by a non–DPP4-like endopeptidase such as FAP. In this study, we report studies done to determine the minimal promdomain length required to inactivate the cytolytic activity of melittin. Subsequently, we substituted putative FAP peptide substrates into this truncated promdomain to identify an FAP-melittin peptide that is selectively toxic to FAP-producing cells. Finally, we evaluated the antitumor effect of an FAP-melittin protoxin after intratumoral injection of peptide into human prostate and breast cancer xenografts.

Materials and Methods

All reagents for Fmoc solid-phase peptide synthesis were purchased from Anaspec. Unless stated otherwise, all other reagents were purchased from Sigma. His-tagged FAP lacking the transmembrane domain was produced and purified in our laboratory as previously described (17). FAP activity was confirmed through activation of the dipeptide substrate Ala-Pro-AFC.

Cell Lines

The human prostate cancer cell line LNCaP and the human breast cancer cell line MCF-7 were purchased from American Type Culture Collection. LNCaP was maintained in RPMI 1640 and MCF-7 in DMEM media supplemented with 10% serum, 1% pen/strep, and 2 mmol/L L-glutamine (Invitrogen) in a 37°C incubator with 5% CO2 and 98% humidity as previously described (23).

Generation of FAP-Transfected Cells

The full-length human FAP cDNA was generated as previously described (17) and cloned into the multiple cloning site of a pIRESneo3 vector (Clontech). Neomycin-selected colonies were obtained and evaluated for FAP expression with 10% serum, 1% pen/strep, and 2 mmol/L L-glutamine. FAP activity was confirmed through activation of the dipeptide substrate Ala-Pro-AFC.

Peptide Synthesis

Promelittin peptides were synthesized on Fmoc-Gln(Trt) Rink amide 4-methyl benzhydrylamine resin and were elongated using standard Fmoc solid-phase peptide conditions on an AAPPTEC Apex 396 peptide synthesizer as previously described (24). The promdomain for each peptide was of variable length, but the mature melittin peptide sequence, NH2-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2, was the same for each peptide. The cleavage and deprotection of the peptides from the resin were carried out using a cleavage cocktail of trifluoroacetic acid/thioanisole/water/phenol/EDT (82.5:5.5:5:2.5, v/v) for 4 h. The peptides were precipitated from the cleavage cocktail using cold ether and dissolved in water for reversed-phase high-performance liquid chromatography purification. Reversed-phase high-performance liquid chromatography purification was

Published OnlineFirst May 5, 2009; DOI: 10.1158/1535-7163.MCT-08-1170
Table 1. Prodomain amino acid sequence of promelittin peptides

<table>
<thead>
<tr>
<th>Toxin</th>
<th>HD_{50} (μmol/L)</th>
<th>Net charge</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM11 APEPEPAPEAEADAEDPEA</td>
<td>&gt;100</td>
<td>-3</td>
</tr>
<tr>
<td>PM11a APEPEPAPEAEADAEDPEA</td>
<td>&gt;100</td>
<td>-3</td>
</tr>
<tr>
<td>PM10 EPEPAPEPAEADAEDPEA</td>
<td>&gt;100</td>
<td>-3</td>
</tr>
<tr>
<td>PM10a PEPEPAPEAEADAEDPEA</td>
<td>&gt;100</td>
<td>-2</td>
</tr>
<tr>
<td>PM9  EAPEPAPEAEADAEDPEA</td>
<td>95.5 ± 3.4</td>
<td>-2</td>
</tr>
<tr>
<td>PM9a EAPEPAPEAEADAEDPEA</td>
<td>73.0 ± 4.7</td>
<td>-1</td>
</tr>
<tr>
<td>PM8  APEPAPEAEADAEDPEA</td>
<td>64.0 ± 4.2</td>
<td>-1</td>
</tr>
<tr>
<td>PM8a PEPEPAEADAEDPEA</td>
<td>59.3 ± 2.7</td>
<td>-1</td>
</tr>
<tr>
<td>PM7  EPEPAEADAEDPEA</td>
<td>66.6 ± 2.9</td>
<td>-1</td>
</tr>
<tr>
<td>PM7a PEAEDAEADAPE</td>
<td>52.0 ± 2.3</td>
<td>0</td>
</tr>
<tr>
<td>PM6  EAEADAEDPEA</td>
<td>55.9 ± 3.5</td>
<td>0</td>
</tr>
<tr>
<td>PM6a AEADAEDPEA</td>
<td>48.4 ± 1.9</td>
<td>1</td>
</tr>
<tr>
<td>PM5  EADAEADAPE</td>
<td>37.6 ± 2.5</td>
<td>1</td>
</tr>
<tr>
<td>PM5a ADAEADAPE</td>
<td>29.2 ± 1.8</td>
<td>2</td>
</tr>
<tr>
<td>PM4  DAEDAEPEA</td>
<td>22.3 ± 1.1</td>
<td>2</td>
</tr>
<tr>
<td>PM4a AEDAEPEA</td>
<td>11.8 ± 0.6</td>
<td>3</td>
</tr>
<tr>
<td>PM3  EADPEA</td>
<td>8.6 ± 0.3</td>
<td>3</td>
</tr>
<tr>
<td>PM3a ADPEA</td>
<td>6.2 ± 0.2</td>
<td>4</td>
</tr>
<tr>
<td>PM2  DPEA</td>
<td>4.7 ± 0.3</td>
<td>4</td>
</tr>
<tr>
<td>PM2a PEA</td>
<td>1.8 ± 0.1</td>
<td>5</td>
</tr>
<tr>
<td>PM1  EA</td>
<td>1.7 ± 0.1</td>
<td>5</td>
</tr>
<tr>
<td>PM1a A</td>
<td>1.5 ± 0.1</td>
<td>6</td>
</tr>
<tr>
<td>PM0</td>
<td>1.3 ± 0.1</td>
<td>6</td>
</tr>
</tbody>
</table>

NOTE: HD_{50} concentration required to lyse 50% of RBC in a 2% RBC solution. Charge, net charge on the full length peptide.

done on a Waters Delta 600 semiprep system using a Phenomenex Luna 10u C18 250 × 10 mm semiprep column. The high-performance liquid chromatography gradient profile was linear starting at 100% solvent A (0.1% trifluoroacetic acid in H₂O) and changing to 100% solvent B (0.1% trifluoroacetic acid in acetonitrile) over 25 min with a flow rate of 8 mL/min. Fractions of the desired purity (>95% as determined using an analytic reversed-phase high-performance liquid chromatography) were pooled and lyophilized. The purified promelittin peptides were mass analyzed on an Applied Biosystems Voyager DE-STR MALDI-TOF mass spectrometer at the Johns Hopkins School of Medicine Mass Spectrometry and Proteomics Facility using a matrix of 10 mg/mL 2,5-dihydroxybenzoic acid in 50% ethanol/water. The mass spectrometer was calibrated using the ProteoMass Peptide MALDI Calibration Kit (Sigma). All spectra were acquired in the positive ion mode.

**Hemolysis Assays**

Hemolysis assays were done as previously described (23). Briefly, peptides were dissolved in DMSO and serially titrated by 2-fold dilution using 1× PBS buffer. The peptides were incubated over a range of concentrations with washed human RBC at a concentration of 2% v/v for 1 h at 37°C. The control for zero hemolysis was RBCs suspended in PBS buffer alone, and the 100% hemolysis control consisted of RBCs in the presence of 1% Triton X-100. After incubation with the peptides, the RBCs were pelleted and 50 μL of each sample were transferred in triplicate to a clear flat-bottomed 96-well polystyrene plate. Hemolysis was assessed by measuring the absorbance of the samples at 540 nm with a Molecular Devices Spectra Max Plus automatic plate reader.

**Promelittin FAP Digestion**

One hundred micrograms of each promelittin peptide were incubated with 2 μg of purified FAP in 200 μL of FAP assay buffer containing 100 mmol/L Tris, 100 mmol/L NaCl (pH 7.8) at 37°C. Aliquots of the digests were taken every hour for 8 h, desalted using P10-C_{18} ZipTips (Millipore), and spotted (0.5 μL) on a MALDI-TOF plate using the 2,5-dihydroxy benzoic acid matrix. Spectra were collected on an Applied Biosystems Voyager DE-STR MALDI-TOF mass spectrometer in positive ion mode.

**Cytotoxicity Assays**

Assays were done using MCF-7 breast cancer cells transfected with a full-length FAP expression vector. Vector-only-transfected MCF-7 cells served as a control. Cells were exposed to peptides over a range of concentrations for 72 h prior and then cell viability was determined using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay (Promega) as previously described and according to manufacturer’s instructions (23).

**In vivo Assays: Tumor Xenograft Studies**

Mouse care and treatment was approved by and done in accordance with the guidelines of the Animal Care and Use Committee of the Johns Hopkins University School of Medicine. Cells maintained under standard conditions were detached by treatment with 0.25% trypsin-EDTA solution and washed in HBSS. They were then suspended in a 60% mixture of Matrigel Matrix (BD Biosciences) in HBSS at a concentration of 2.0 × 10⁶ cells per 100 μL of solution. LNCaP cells were then injected into the subcutis overlying the rear flanks of 6-week-old male nude mice (Harlan). MCF-7 cells were injected s.c. into 6-wk-old female nude mice previously implanted s.c. with a slow release estrogen pellet (0.72 mg of 17β-estradiol; Innovative Research of America) in the contralateral flank. Weekly tumor measurements were made with calipers and the tumor volume (in cm³) was calculated by the formula 0.5236 × L × W × H. The mice were euthanized by CO₂ overdose, and the tumors were weighed and processed for histochemical analysis as previously described (23). Balb/c mice (Harlan) were used for i.v. toxicity studies as previously described (23).

**Statistical Analysis**

For the in vitro proliferation studies, P values were derived from the Student’s t test. All statistical tests were two-sided, and P value of <0.05 was considered to be statistically significant. For the in vivo studies, data, presented as mean ± SE, were evaluated using ANOVA analysis. P value of <0.05 was considered statistically significant.

**Results**

**Promelittin Prodomain Truncation**

A total of 22 promelittin peptides, representing every possible prodomain length, were synthesized (Table 1). Using the truncated promelittin peptides, we investigated how much of the prodomain was necessary to inhibit the

1380  FAP-Activated Promelittin Protoxin

Mol Cancer Ther 2009;8(5). May 2009

Published OnlineFirst May 5, 2009; DOI: 10.1158/1535-7163.MCT-08-1170
The cytolytic ability of melittin. The goal was to find the minimal length melittin prodomain that could be subsequently modified to produce the minimal length FAP-activated melittin peptide toxin. Whereas PM11 represents the full-length prodomain, peptides PM0-PM10 represent products of the stepwise two amino acid cleavage of promelittin by DPP4. Peptides PM1a-PM11a are non-DPP4 substrates because they do not contain dipeptide units at the NH₂ terminus ending with either proline or alanine. To assess the relative degree of inhibition of the lytic ability of each promelittin peptide toward eukaryotic cells, human erythrocytes were used as a model membrane. The hemolytic dose necessary to lyse 50% of the erythrocytes (i.e., HD₅₀) was determined for each promelittin peptide (Table 1). These studies revealed that the promelittin peptides containing the longest prodomains were the least hemolytic toward human erythrocytes. The full-length promelittin peptide (PM11), PM11a, PM10, and PM10a, all had HD₅₀ values above 100 μmol/L. Appreciable hemolysis was not observed until approximately half of the pro-domain had been removed. PM6, with a 12 amino acid pro-domain sequence and a net charge of 0, had an HD₅₀ of 55.9 μmol/L. As the pro-domain sequence decreased one amino acid at a time and the net negative charge of the peptide increased, the HD₅₀ for each peptide steadily decreased (Table 1). PM0 (melittin) was found to have an HD₅₀ of 1.3 μmol/L. Likewise, the 7 shortest promelittin peptides were hemolytic with HD₅₀ values at or below 10 μmol/L.

Based on these results, the 14 amino acid pro-domain length of PM7, which had an HD₅₀ of 66.6 μmol/L, was selected for further studies aimed at developing an FAP-activated toxin. PM7 was found to be ~50-fold less hemolytic than the fully processed melittin. Although longer length prodomains had higher HD₅₀ values in the hemolysis assay, the 40 amino acid PM7 was selected because this starting peptide length allowed for the introduction of modifications and additions to the prodomain that would produce peptides that were <50 amino acids.

<table>
<thead>
<tr>
<th>Prodomain Sequence</th>
<th>Observed Parental Ion (% Relative Intensity)</th>
<th>Observed Cleavage Product (% Relative Intensity)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAP1 EP[EAEADAEAGP]EA-mel</td>
<td>3986.75</td>
<td>4214.71 (20)</td>
</tr>
<tr>
<td>FAP2 EPEAEADAEAGPA-mel</td>
<td>3046.89</td>
<td>2918.32 (100)</td>
</tr>
<tr>
<td>FAP3 EPEAEADAEADPEGPA-mel</td>
<td>2918.48</td>
<td>4084.66 (60)</td>
</tr>
<tr>
<td>FAP4 EPEAEAEADPEASGEAGPA-mel</td>
<td>2918.93</td>
<td>2918.48 (70)</td>
</tr>
<tr>
<td>FAP5 EPEAEAEADPEAPGPPGP-mel</td>
<td>2846.13</td>
<td>2846.13 (15)</td>
</tr>
</tbody>
</table>

**Figure 1.** FAP cleavage of the modified promelittin peptides. The prodomain sequence of modified protoxins (FAP 1-5) with cleavage site and mass of cleavage fragment delineated. MALDI-TOF analysis was used to evaluate the extent of cleavage. The relative intensity of each mass fragment is based on a comparison of the relative peak height for each individual trace, with the largest peak for each experiment arbitrarily set to 100. Bottom, representative MALDI trace for FAP1 and FAP2 (100 μg) at time 0 and 8 h after exposure to active FAP (2 μg total).
in length. Peptides longer than 50 amino acids were technically difficult to synthesize and this precluded the use of longer length promelittins (e.g., PM11) as the starting sequence.

**Generation of an FAP-Cleavable Promelittin Protoxins**

Previous studies in our laboratory and others have documented that the most preferred FAP-cleavable peptide sequences contain Pro in the P1 position and Gly in the P2 position with a suggestion that Ala in the P'1 position is also favored (17, 25). Based on our previous studies characterizing FAP cleavage substrates from a map of cleavage sites within human gelatin, five candidate protoxins were synthesized using the prodomain of PM7 (i.e., FAP1-5; Fig. 1A; ref. 16). In FAP1, the Asp-4 of the PM7 prodomain was changed to a Gly to reproduce the Gly-Pro preference in the P1 and P2 positions ascribed to FAP (17). Because the effect on the ability of FAP to hydrolyze a peptide containing an acidic Glu residue in the P1 position was not known, FAP2 was designed such that the prodomain sequence was kept the same as that for FAP1 with the exception that Glu-2 of the prodomain of FAP1 was removed to create the FAP preferred P2-P1-P’1 sequence of Gly-Pro-Ala. For FAP3, the P2-P1-P’1 sequence of Gly-Pro-Ala was inserted between the NH2 terminus of melittin and the full-length native PM7 prodomain sequence. FAP4 had a seven amino acid FAP cleavable peptide substrate (SGEAGPA) inserted between the NH2 terminus and the PM7 prodomain, whereas FAP5 had a repetitive (Prol-Gly-Pro)2 motif inserted between the NH2 terminus of melittin and the prodomain of PM7. FAP4 and FAP5 were the two largest peptides synthesized, 46 and 47 amino acids, respectively. FAP2 was the shortest, consisting of only 39 amino acids. The hemolytic activity of these FAP candidate protoxins was assayed and all were found to have HD50 values between 50 and 70 μmol/L (Table 2).

**FAP Cleavage Assays**

To assess FAP cleavage, the FAP candidate protoxins were assayed in vitro with purified recombinant FAP to characterize the extent of FAP-mediated cleavage. The peptides (100 μg) were digested with FAP (2 μg) for a total of 8 hours at 37°C. Every 2 hours, aliquots were taken and the progress of the digest was monitored using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Fig. 1). After 8 hours, the only protoxin that was completely digested by FAP was FAP2 (Fig. 1). The digested FAP2 yielded only 1 cleavage product with a mass of 2,918.32 m/z, corresponding to the hydrolysis of the Gly-ProAla bond. FAP1, which differed from FAP2 by only one Glu residue, did show some of the desired cleavage product at 3,046.89 m/z (Fig. 1). However, the FAP1 digest was incomplete, leaving uncut starting material and other cleavage by-products. FAP3, FAP4, and FAP5 were cleaved to varying degrees, but none were cleaved as well as FAP2 (Fig. 1). Finally, although mature melittin also contains an internal proline residue, MALDI-TOF analysis showed that it was not cleaved by FAP (data not shown).

**FAP Promelittin Protoxins Selectively Kill FAP-Expressing Human Breast Cancer Cell Lines**

To evaluate the selectivity of each FAP-activated protoxin for the ability to kill FAP-positive versus FAP-negative cancer cells, we transfected the human breast cancer cell line MCF-7 with either FAP or vector only controls. These cells were then used to assess the effect of each protoxin on growth as assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium bromide assay. In this assay, mature melittin showed no selectivity and was able to kill both cell lines at approximately equally low micromolar concentrations (Table 2). Compared with melittin, the modified promelittin peptides were ~30- to 40-fold less toxic against the vector only–transfected FAP-negative MCF-7 cells. In contrast, against the transfected FAP-producing cell line, FAP2 was the most toxic peptide surveyed with an IC50 of 5.2 μmol/L. This peptide was also the most selective and was ~7-fold more active against the FAP-positive versus FAP-negative MCF-7 cells. All of the other promelittin peptides had fold differences in cytotoxicity of less than two (Table 2). FAP2 was the only protoxin in this series that showed a significant therapeutic index in vitro.

To eliminate the potential for nonspecific cleavage of the FAP2 sequence by DPP4, we subsequently generated a DPP4-“resistant” version of FAP2 by adding an acetylated NH2-terminal glycine to the FAP2 peptide to generate Ac-FAP2. Ac-FAP2 was cleaved by FAP to the same extent as FAP2 (data not shown) and had the highest HD50 (72 μmol/L) of all of the FAP-activated protoxins (Table 2). This acetylated peptide showed increased specificity with an IC50 of 47.9 versus 35.1 μmol/L for FAP2 against FAP-negative cells. However, Ac-FAP6 was nearly as potent as FAP2 with an IC50 value of 6.1 μmol/L against FAP-positive cells for an overall higher ~8-fold difference in toxicity against FAP-positive and FAP-negative cells.

**In vivo Antitumor Activity of FAP Promelittin Protoxins**

Before performing in vivo efficacy studies, we did toxicity studies in vivo with the administration of the protoxins i.v. and intratumorally. Melittin is a nonspecific cytolytic toxin. Therefore, as expected, melittin was highly toxic to mice with an i.v. LD100 (i.e., single dose that kills 100%) of 8.1 μmol/L.

| Table 2. HD50 values and cytotoxicity of FAP Melittin protoxins against FAP-negative and FAP-positive MCF-7 human breast cancer cells |
|---|---|---|---|
| Toxin | HD50 (μmol/L) | IC50 (μmol/L) |
| | FAP neg | FAP pos | Fold diff |
| FAP1 | 56.9 ± 3.1 | 45.6 ± 5.6 | 26.8 ± 1.1 | 1.7 |
| FAP2 | 54.2 ± 2.2 | 35.1 ± 2.0 | 5.2 ± 0.4 | 6.7 |
| FAP3 | 60.0 ± 3.7 | 33.1 ± 2.3 | 18.9 ± 1.7 | 1.8 |
| FAP4 | 70.5 ± 5.1 | 50.1 ± 4.9 | 28.1 ± 2.2 | 1.8 |
| FAP5 | 67.5 ± 3.5 | 27.6 ± 1.2 | 18.3 ± 2.0 | 1.5 |
| Ac-FAP6 | 72.2 ± 3.6 | 47.9 ± 2.9 | 6.1 ± 0.3 | 7.9 |
| Melittin | 1.3 ± 0.1 | 1.4 ± 0.1 | 1.3 ± 0.2 | 1.1 |

Abbreviations: FAP neg, FAP negative; FAP pos, FAP positive; fold diff, fold difference.

Mol Cancer Ther 2009;8(5). May 2009
animals) of ~3 mg/kg, i.v., a dose of 1 mg/kg of melittin was the maximally tolerated dose. In contrast, for PM11, FAP2, and Ac-FAP6, a single dose of 40 mg/kg i.v. was tolerated in Balb-c mice, whereas a dose of 100 mg/kg was 100% lethal. The LD100 for FAP2 was subsequently found to be lower in tumor-bearing nude mice used in efficacy experiments as a single 40 mg/kg i.v. dose proved lethal to all mice within 1 week posttreatment. For the intratumoral injection studies, the maximum tolerated dose of intratumoral melittin was determined to be 5.7 mg/kg (50 nmoles). In contrast, an intratumoral dose of 40 mg/kg (250 nmoles) of FAP2 was well-tolerated, whereas a dose of 200 mg/kg (1,250 nmoles) was lethal to ~33% of treated animals by 24 hours posttreatment.

A number of studies have documented that FAP expression in mouse stromal cells occurs in a wide variety of human cancer xenografts (13, 26, 27). On the basis of these dose finding studies, an initial cohort of animals (n = 6 per group) bearing LNCaP human prostate cancer xenografts received a single intratumoral injection of either 40 or 200 mg/kg of FAP2 (Fig. 2). Tumors were then imaged serially over a 34-day period. Representative results are shown in Fig. 2. Treated tumors developed a necrotic center and overlying eschar, which eventually healed as the underlying tumor regressed over the observation period. Complete regressions were observed in select animals in the 200 mg/kg group (Fig. 2), but this dose level also resulted in the death of 1 of 3 of the treated animals. No complete regressions were observed in the 40 mg/kg dosing group.

The next experiment was designed to compare the extent of FAP specific versus nonspecific killing after the injection of a series of promelittin toxins into human MCF-7 breast cancer xenografts. This line was selected based on previous studies demonstrating that MCF-7 possesses a moderate amount of stroma and can induce expression of human FAP by human fibroblasts coinoculated with MCF-7 cells (28). For these studies, we compared the single dose efficacy of Ac-FAP6 (FAP-activated, DPP4-resistant, HD50 of 72 μmol/L) to PM11 (FAP-resistant, DPP4-activated, HD50 of >100 μmol/L). In addition, to generate a toxin that would not be cleaved by FAP or DPP4, we evaluated the effects of acetylating the amino terminus of the PM toxins. In this analysis, we determined that acetylation can lower the HD50 compared with the unacetylated protoxin in some instances. From this analysis, we selected the acetylated version of sequence PM9 for in vivo studies because this acetylated protoxin had the highest HD50 of all of the acetylated peptides tested. Although PM9 had an HD50 of 95 μmol/L, Ac-PM9 had an HD50 of 76 μmol/L, which was similar to the HD50 for Ac-FAP-6. Like Ac-FAP6, Ac-PM 9 is not a substrate for dipeptidyl peptidase IV due to acetylation of the amino terminus and is not cleaved by FAP due to lack of the FAP-preferred Gly-Pro dipeptide in the prodomain. Therefore Ac-PM9 can be considered FAP resistant and DPP4 resistant.

Based on previous toxicity studies, tumor-bearing animals were treated with a single intratumoral dose of 250 nmoles (~40-50 mg/kg) of each of these promelittin toxins. Tumors (n = 3 per group) were then harvested 96 hours postinjection, fixed, and stained. Areas of necrotic tissue were easily seen under low-power magnification with higher power magnification demonstrating areas with pyknotic nuclei in a field of cellular debris (Fig. 3A). Under low-power magnification using image analysis, the total area of the tumor slice was determined as previously described (23). Subsequently, the total area of nonviable tumor tissue was determined and the % area of necrosis was determined from the ratio of these two areas (Fig. 3B). Using this methodology, injection of PM11 resulted in tumors with ~25% necrosis of total tumor cross-sectional area, which was not significantly different than the 16% necrosis seen in control tumors injected with saline (Fig. 3C). Ac-PM9 induced necrosis that was not significantly different than that seen for PM11 (Fig. 3C). In contrast, Ac-FAP6 injection resulted in significant increase in the area of necrosis with ~60% necrosis of tumors at 96 hours postinjection, consistent with
the enhanced distribution and activation of the Ac-FAP6 toxin compared with the non-FAP activated PM11 and Ac-PM9 toxins (Fig. 3C).

In the final experiment, the effect of Ac-FAP6 on the growth rate of tumors after intratumoral injection was compared with the growth rate of saline injected controls (Fig. 4A). Studies were done using an intratumoral treatment approach to evaluate the full extent of activation of the FAP-activated toxin within tumor tissue. After randomization to afford groups of relatively equal starting average tumor size, animals (n = 8 per group) received a single intratumoral injection of either 45 mg/kg (250 nmoles) of Ac-FAP6 or saline and were then followed for an additional 2 weeks posttreatment. No animal deaths or morbidity were observed in either group. In the saline controls, 7 of 8 animals had a doubling of tumor size by day 14 (Fig. 4B). In contrast, only 2 of 8 Ac-FAP6 animals had a doubling of tumor size over this time period (Fig. 4B). Two of the Ac-FAP6–treated animals had a >20% reduction in starting tumor size, with 1 of these animals having a >50% reduction. None of the control animals had any significant reduction in tumor size over the measurement period. A number of the Ac-FAP6 animals had an initial increase in tumor size at day 4 posttreatment followed by a 20% to 65% decrease in size at day 7 posttreatment, possibly due to an initial acute inflammation within the tumor.

**Discussion**

The goal of these studies was to show the feasibility of targeting the unique proteolytic activity of FAP, a membrane-bound serine protease that is expressed on the surface of reactive fibroblasts present within the stroma of most human tumors. Given its restricted expression in the reactive stroma of potentially >90% of epithelial cancers studied (7), FAP represents an attractive target for tumor-directed therapies. In this study, to provide the initial proof of concept data, we focused on a peptide-based protoxin strategy due to the ease of synthesis and the known ability of FAP to function as an endopeptidase. We showed that the inhibitory prodomain of melittin, a well-characterized toxin produced by the honeybee, could be modified to a form that was no longer hydrolyzed by the native activator protease DPP4 but, instead, was hydrolyzed by FAP.

Although FAP has only recently come to attention as a putative tumor-specific target, considerable effort has already been expended to develop FAP-based therapies. The most obvious therapeutic approach would be to develop inhibitors of FAP function such as monoclonal antibodies (29, 30) or small molecule inhibitors (31–33). These approaches are under preclinical and clinical evaluation. Such strategies would potentially produce a therapeutic benefit if FAP were involved in the promotion of growth within tumors. However, studies to date suggest that the role of FAP in tumor growth may be highly contextual and in some cases, FAP expression may itself be growth inhibitory to tumors (33, 34). Thus, in contrast to these inhibitory strategies, the protoxin strategy described here can be successful regardless of the role of FAP in tumor biology as it takes advantage of the enzymatic activity of FAP to selectively activate a highly potent cytotoxin in the peritumoral fluid. Such activation should not only lead to death of tumor stromal cells but will also generate a significant bystander effect leading to death of tumor cells and endothelial cells within and surrounding the stromal compartment.

Although these studies provide proof of concept, the therapeutic application of this FAP-activated promelittin toxin is limited and would most likely only be useful in settings

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Comparison of the effect of promelittin toxins on the viability of human MCF-7 breast cancer xenografts. A, H&E-stained tissue from xenograft treated with Ac-FAP6 shows unaffected tumor adjacent to the necrotic area at ×100 and ×400 magnification. Top, white arrow, area of necrotic tissue; black arrow, strand of stroma within the background of tumor cells. Bottom, blue arrow, pyknotic nuclei consistent with necrotic death; orange arrow, nuclei from a viable cell unaffected by toxin. B, evaluation of the extent of necrosis produced by the intratumoral injection of Ac-FAP6 at 96 h postinjection. H&E-stained cross-section of representative tumor treated with either Ac-FAP6 (45 mg/kg) or saline shows increased areas of necrosis (pale pink area outlined in green) in a background of viable tumor (reddish purple). Representative images shown at ×0.75 magnification; C, image analysis used to determine the area of necrosis calculated as the ratio of the cross-sectional area of nonviable tumor to area of total tumor for tumors treated intra-tumorally with single dose of 250 nmoles of indicated toxin or normal saline 1*, P < 0.05 by Student’s t test for Ac-FAP6 versus saline control.
where intratumoral/intraorgan injection is possible. As an example of the applicability of such an approach, we described the development of a prostate-specific antigen–activated bacterial protoxin that is currently undergoing clinical testing as an intraprostatic therapy for the treatment of locally recurrent prostate cancer and benign prostatic hyperplasia (23). A similar strategy could be envisioned for the FAP-activated toxin. Because increased FAP expression has been found in most tumors evaluated, this approach could have a wider intratumoral application than that for a tissue-restricted protease such as prostate-specific antigen.

For these studies, we used an intratumoral treatment based approach to document that FAP-activated peptide toxin could produce a significant antitumor effect. Ideally, systemic delivery of these peptide toxins would be the preferred route administration. However, the ability of these promelittin toxins to induce hemolysis even when not fully processed represents a major hurdle to this application. In our hands, a single dose of 40 mg/kg of the FAP2 toxin, which was well-tolerated and effective intratumorally, proved lethal to tumor-bearing animals when administered i.v. This is most likely due to the fact that this dose would produce a potential maximum blood concentration that is >100 μmol/L, which is above the HD50 for this promelittin toxin. Further development of this promelittin peptide-based approach as a systemic therapy would require substantial modification to generate a protoxin that was unable to cause hemolysis even at millimolar concentrations. Alternatively, potent cytotoxic agents, preferably ones that did not produce hemolysis could be coupled to an FAP-specific peptide to generate an inactive prodrug that is selectively activated by FAP-expressing cells within the tumor stroma. Our laboratory has already adopted such an approach to generate prostate tissue specific prodrugs that are activated by the proteolytic activity of prostate-specific antigen, human glandular kallikrein 2, and prostate-specific membrane antigen (35–37). In ongoing studies in our laboratory, we are evaluating a series of such FAP-activated produgs that can be used to selectively target and kill cells within the tumor stroma as therapy for a wide variety of human cancers.

Figure 4. Antitumor effect of a single intratumoral dose of Ac-FAP6 against MCF-7 human breast cancer xenografts. A, average tumor volume of saline control versus Ac-FAP6 (45 mg/kg) over a 14-d period (n = 8 mice per group; P < 0.05 for days 4, 7, and 11 by ANOVA); B, growth of individual saline-treated control tumors to Ac-FAP6–treated tumors over a 14-d period. Each trace represents the growth of an individual MCF-7 xenograft in each mouse.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Marc Rosen for the excellent technical assistance in performing animal studies and the Johns Hopkins School of Medicine Mass Spectrometry and Proteomics Core Facility for assistance with the characterization of peptide toxins.

References
Molecular Cancer Therapeutics

Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin


Mol Cancer Ther  Published OnlineFirst May 5, 2009.

Updated version  Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-08-1170

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/early/2009/05/04/1535-7163.MCT-08-1170. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.